Kamada Ltd. (KMDA) News
Filter KMDA News Items
KMDA News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
KMDA News Highlights
- KMDA's 30 day story count now stands at 6.
- Over the past 10 days, the trend for KMDA's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about KMDA are RARE and AG.
Latest KMDA News From Around the Web
Below are the latest news stories about KAMADA LTD that investors may wish to consider to help them evaluate KMDA as an investment opportunity.
KMDA: 1Q23 Revenues of $30.7 Million; Continue to Expect 2023 Revenues of $138 Million to $146 Million…By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Financial Update On May 24, 2023, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the first quarter of 2023. Kamada reported revenues of $30.7 million, which was a 9% increase over the first quarter of 2022. The revenue consisted of $24.1 million from proprietary products and $6.6 million from the distribution business. |
Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability GuidanceTotal Revenues for First Quarter of 2023 were $30.7 Million, Up 9% Year-over-YearFirst Quarter 2023 EBITDA of $3.8 Million, Increase of 16% Year-over-YearSolid First Quarter Results and Expected Continued Momentum Supported by Multiple Growth Drivers Anticipated to Drive Full-Year 2023 EBITDA Growth of Over 30% Year-over-YearAnnounced $60 Million Private Placement with FIMI Opportunity FundsReceived FDA Approval to Manufacture CYTOGAM® at the Company’s Israeli Facility; Expected to Positively Im |
Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate SecretaryREHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that following the recently announced $60 million private placement with the FIMI Opportunity Funds, which is expected to contribute to accelerating the growth o |
Kamada Announces $60 Million Private Placement with FIMI Opportunity FundsFunding to Support Kamada’s Growth Plans and Execution of Strategic Business Development OpportunitiesREHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it has entered into a share purchase agreement (the “P |
Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023REHOVOT, Israel and HOBOKEN, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2023, prior to the open of the U.S. financial markets on Wednesday, May 24, 2023. Kamada management will host an investm |
Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in SwitzerlandSwitzerland is the first European country to approve Glassia®, which received U.S. FDA approval in 2010Glassia will be commercialized by IDEOGEN AG in Switzerland and the therapy is expected to be available to patients and providers during the second half of 2023The current Alpha-1 Antitrypsin Deficiency (AATD) market in Switzerland is estimated to be over $15 million annually REHOVOT, Israel and HOBOKEN, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commerc |
Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in IsraelSales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021 with Approximately $23 Million in Revenues in 2022, and Gross Margins Over 50%Approval to Manufacture CYTOGAM at Kamada’s Facility to Positively Impact Plant Utilization and Efficiency REHOVOT, Israel and HOBOKEN, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that |
KMDA: 2022 Revenue of $129 Million; Expected 2023 Revenues of $138 Million to $146 Million and Continued Positive Operating Cash Flow…By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Financial Update On March 15, 2023, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the fourth quarter and full year 2022 and provided a business update. Kamada reported revenues of $129.3 million, which met the company’s previously announced guidance, and was a 25% increase compared to fiscal year 2021. The increase was |
Kamada Ltd. (NASDAQ:KMDA) Q4 2022 Earnings Call TranscriptKamada Ltd. (NASDAQ:KMDA) Q4 2022 Earnings Call Transcript March 15, 2023 Operator: Greetings. Welcome to the Kamada Ltd. Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. Please note, this conference is being recorded. At this time, […] |
Kamada Issues 2023 CEO Letter to ShareholdersREHOVOT, Israel and HOBOKEN, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer. Dear Shareholders, Colleagues and Business Partners: The recently completed 2022 year was a transformational period for Ka |